A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

NCT06041802 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa

Sponsor

Merck Sharp & Dohme LLC